A Phase 1, Randomised, Placebo‑Controlled, Ascending Single and Multiple Dose Safety, Tolerability, Pharmacokinetic and Food Effect Study of PAT‑1251 in Healthy Adult Subjects

Trial Profile

A Phase 1, Randomised, Placebo‑Controlled, Ascending Single and Multiple Dose Safety, Tolerability, Pharmacokinetic and Food Effect Study of PAT‑1251 in Healthy Adult Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Aug 2017

At a glance

  • Drugs PAT 1251 (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Adverse reactions
  • Sponsors PharmAkea Therapeutics
  • Most Recent Events

    • 22 Aug 2017 According to a PharmAkea Therapeutics media release, the data from this study will inform the dose selection and study design for a subsequent Phase 2 proof-of-concept study in Idiopathic-pulmonary-fibrosis.
    • 22 Aug 2017 Results published in a PharmAkea Therapeutics media release.
    • 28 Nov 2016 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top